Advertisement
NBIX or OPK or PRQR
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NBIX’s FA Score shows that 0 FA rating(s) are green whileOPK’s FA Score has 0 green FA rating(s), and PRQR’s FA Score reflects 0 green FA rating(s).
- NBIX’s FA Score: 0 green, 5 red.
- OPK’s FA Score: 0 green, 5 red.
- PRQR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NBIX’s TA Score shows that 4 TA indicator(s) are bullish while OPK’s TA Score has 7 bullish TA indicator(s), and PRQR’s TA Score reflects 2 bullish TA indicator(s).
- NBIX’s TA Score: 4 bullish, 4 bearish.
- OPK’s TA Score: 7 bullish, 2 bearish.
- PRQR’s TA Score: 2 bullish, 4 bearish.
Price Growth
NBIX (@Pharmaceuticals: Other) experienced а -0.02% price change this week, while OPK (@Medical Specialties) price change was -1.45% , and PRQR (@Biotechnology) price fluctuated +2.17% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.61%. For the same industry, the average monthly price growth was +3.66%, and the average quarterly price growth was +73.67%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.35%. For the same industry, the average monthly price growth was +1.87%, and the average quarterly price growth was -1.26%.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.56%. For the same industry, the average monthly price growth was +10.24%, and the average quarterly price growth was +39.21%.
Reported Earning Dates
NBIX is expected to report earnings on Nov 04, 2025.
OPK is expected to report earnings on Nov 05, 2025.
PRQR is expected to report earnings on Nov 05, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (-0.61% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-1.35% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Biotechnology (+2.56% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| NBIX | OPK | PRQR | |
| Capitalization | 13.7B | 920M | 248M |
| EBITDA | 358M | -65.52M | -26.88M |
| Gain YTD | -2.212 | -7.483 | -11.321 |
| P/E Ratio | 57.20 | 26.11 | N/A |
| Revenue | 1.89B | 863M | 19M |
| Total Cash | 1.03B | 95.9M | 132M |
| Total Debt | 428M | 327M | 16.9M |
NBIX | OPK | PRQR | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 81 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 67 Overvalued | 36 Fair valued | |
PROFIT vs RISK RATING 1..100 | 82 | 100 | 100 | |
SMR RATING 1..100 | 61 | 90 | 97 | |
PRICE GROWTH RATING 1..100 | 50 | 77 | 37 | |
P/E GROWTH RATING 1..100 | 34 | 98 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRQR's Valuation (36) in the Biotechnology industry is in the same range as OPK (67) and is somewhat better than the same rating for NBIX (72). This means that PRQR's stock grew similarly to OPK’s and somewhat faster than NBIX’s over the last 12 months.
NBIX's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as PRQR (100) and is in the same range as OPK (100). This means that NBIX's stock grew similarly to PRQR’s and similarly to OPK’s over the last 12 months.
NBIX's SMR Rating (61) in the Biotechnology industry is in the same range as OPK (90) and is somewhat better than the same rating for PRQR (97). This means that NBIX's stock grew similarly to OPK’s and somewhat faster than PRQR’s over the last 12 months.
PRQR's Price Growth Rating (37) in the Biotechnology industry is in the same range as NBIX (50) and is somewhat better than the same rating for OPK (77). This means that PRQR's stock grew similarly to NBIX’s and somewhat faster than OPK’s over the last 12 months.
NBIX's P/E Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for OPK (98) and is significantly better than the same rating for PRQR (100). This means that NBIX's stock grew somewhat faster than OPK’s and significantly faster than PRQR’s over the last 12 months.
| NBIX | OPK | PRQR | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 57% | N/A | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 61% | 1 day ago 79% | 1 day ago 87% |
| Momentum ODDS (%) | 1 day ago 69% | 1 day ago 77% | N/A |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 80% | N/A |
| TrendWeek ODDS (%) | 1 day ago 61% | 1 day ago 81% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 72% | 1 day ago 72% | 1 day ago 82% |
| Advances ODDS (%) | 7 days ago 72% | 8 days ago 74% | 7 days ago 85% |
| Declines ODDS (%) | 20 days ago 62% | 2 days ago 80% | 1 day ago 84% |
| BollingerBands ODDS (%) | 1 day ago 77% | 1 day ago 82% | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 74% | 1 day ago 73% | 1 day ago 82% |
Advertisement